We support drug development through clinical research, focusing on oncology, and respiratory and infectious diseases.

With cross-disciplinary expertise, state-of-the-art facilities and far-reaching recruitment capabilities, we can safely shorten the time to market and realize the true potential of innovative drug compounds around the world.

We recently overcame challenges during a phase III clinical trial studying the safety and efficacy of an influenza treatment. This global multicenter trial, the largest influenza study performed to date, took place over 5 influenza seasons at 161 sites in both hemispheres and involved approximately 2000 patients.

Finding patients to participate in the study was challenging. Patients had to be enrolled within 24 to 48 hours after symptoms appeared. This meant that an influenza diagnosis had to be confirmed within this window. Seasonality and geographical patterns of influenza also affected enrollment. Because a large number of subjects had to be enrolled in a short time, additional resources to support medical monitoring and diagnostics were required.

As a result of SGS’s efforts as well as good study design, recruitment targets were met. On-site retraining of swabbing and sampling handling increased compliance and allowed samples to be delivered on time. The study team, including CRAs, medical monitors and DMs, ensured that data was cleaned on time and project milestones were met.

This is the second in a series of case studies demonstrating how we use our scientific and technical expertise and extensive resources to support clinical research and drug development.

Find out more about SGS infectious diseases services.

Read about an oncology clinical trial.